Study Enhances Effectiveness of CAR-NK Cells in Tumor Destruction
A recent study by researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy has demonstrated that engineered NK-92 cells with specific chimeric antigen receptors can improve tumor-targeting capabilities.
Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) have conducted a study focusing on the NK-92 cell line to explore new models of chimeric antigen receptors (CARs). This research specifically examined the impact of certain costimulatory domains, including 2B4 and DAP12, on the performance of these cells.
Study Findings
The findings indicated that the incorporation of these costimulatory domains significantly enhanced the NK-92 cells' readiness to attack tumors. The modifications made to the CARs appear to increase the cells' ability to effectively destroy cancerous cells. This advancement in CAR-NK cell technology could lead to improved therapeutic options for cancer treatment. The results of this study were published in the journal Frontiers in Immunology.
According to a report by Medical Xpress, the implications of this research could be substantial for future cancer therapies, as it suggests a pathway for making immune cells more effective in targeting and eliminating tumors. The work highlights ongoing efforts to optimize cell-based therapies in the fight against cancer.